12-Hour Compared With 24-Hour Postpartum Magnesium Sulfate Therapy in Preeclampsia

Authors:

Abstract
INTRODUCTION: The objective of this study was comparative use of magnesium sulfate for 12 compared with 24 hours in postpartum women with stable severe preeclampsia. METHODS: An open, randomized clinical trial was conducted with 120 postpartum women with severe preeclampsia; 60 were allocated to receive magnesium sulfate for 24 hours and 60 for 12 hours. The analysis was by intention to treat and the intervention was not masked. RESULTS: Abbreviated magnesium sulfate therapy (12 hours) was associated with less exposure to the drug, and clinical outcomes were similar in both groups. No cases of eclampsia were found and there was no need to reinitiate treatment after completing the scheduled magnesium sulfate therapy in either of the two groups. Magnesium sulfate therapy was extended in only three patients in the group of women using the medication for 12 hours. In addition, in the 12-hour group, significant time reductions were found concerning the postpartum use of an indwelling bladder catheter, time until the start of deambulation, and the interval between delivery and the mother's contact with her newborn. CONCLUSION: Abbreviated postpartum magnesium sulfate therapy was associated with less exposure to the drug, similar outcomes, and with benefits in patients with stable severe preeclampsia.